Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.59 |
| ▸ | ITGAV | P06756 | 6/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.59 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.59 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.59 |
| ▸ | CASR | P41180 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545844 | 0.95 | ITGAV (0.61) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL6546323 | 0.94 | ITGAV (0.54) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL6546024 | 0.94 | ITGAV (0.66) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL6545220 | 0.90 | CASR (0.53) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL6545782 | 0.89 | ITGAV (0.56) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL6802152 | 0.89 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL6545655 | 0.88 | ITGAV (0.60) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL6546439 | 0.88 | ITGAV (0.57) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL6545895 | 0.88 | CASR (0.55) | ITGB3ITGAVITGA2BITGB6ITGB5 | |
| SCHEMBL6546349 | 0.87 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB6ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142877-A1 | Ligands of the $g(a)v$g(b)6 integrin | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | US | claimed |
| EP-1379495-A2 | LIGANDS OF THE ALPHA-V-BETA 6 INTEGRIN | MERCK PATENT GmbH (DE) | 2004-01-14 | — | — | EP | claimed |
| WO-2002083627-A2 | LIGANDS DES INTEGRINS AVSS6 | MERCK PATENT GMBH (DE) | 2002-10-24 | — | — | WO | claimed |
| US-20040142877-A1 | Ligands of the $g(a)v$g(b)6 integrin | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | US | disclosed |
| EP-1379495-A2 | LIGANDS OF THE ALPHA-V-BETA 6 INTEGRIN | MERCK PATENT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002083627-A2 | LIGANDS DES INTEGRINS AVSS6 | MERCK PATENT GMBH (DE) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142877-A1 | Ligands of the $g(a)v$g(b)6 integrin | ITGB6, ITGAV, ITGB1 | ITGB3 13/4885ITGAV 2/4885ITGA2B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.